Targeting C5aR1 Increases the Therapeutic Window of Radiotherapy
Olcina, M. M.; Melemenidis, S.; Nambiar, D. K.; Kim, R. K.; Casey, K. M.; von Eyben, R.; Woodruff, T. M.; Graves, E. G.; Le, Q.-T.; Stucki, M.; Giaccia, A. J.
Show abstract
Engaging innate immune pathways is emerging as a productive way of achieving durable anti-tumor responses. However, systemic administration of these therapies can result in toxicity, deemed to be particularly problematic when combined with current standard-of-care cytotoxic treatments such as radiotherapy. Increasing the therapeutic window of radiotherapy may be achieved by using targeted therapies, however, few pre-clinical studies investigate both tumor and normal tissue responses in detail. Here we show that targeting innate immune receptor C5aR1 improves tumor radiation response while reducing radiation-induced normal tissue toxicity, thereby increasing the therapeutic window. Genetically or pharmacologically targeting C5aR1 increases both IL-10 expression in the small intestine and IL-10 secretion by tumor cells. Increased IL-10 attenuates RelA phosphorylation and increases apoptosis in tumor cells, leading to improved radiation responses in murine models. Of note, these radiosensitizing effects are tumor-specific since, in the gastrointestinal tract, targeting C5aR1 instead results in decreased crypt cell apoptosis reduced signs of histological damage and improved survival following total abdominal irradiation in mice. Furthermore, the potent and orally active C5aR1 inhibitor, PMX205, improves tumor radiation responses even in a context of reduced/absent CD8+ T cell infiltration. These data indicate that PMX205 can modulate cancer-cell intrinsic functions to potentiate anti-tumor radiation responses even in tumors displaying features of T-cell deficiency or exclusion. Finally, using a preclinical murine model allowing the simultaneous assessment of tumor and normal tissue radiation responses, we show that PMX205 treatment reduces histological and functional markers of small-bowel toxicity while affording a positive tumor response. Our data, therefore, suggest that targeting C5aR1 could be a promising approach for increasing the therapeutic window of radiotherapy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity 95%
- Immune stromal components impede biological effectiveness of carbon ion therapy in a preclinical model of pancreatic ductal adenocarcinoma 95%
- Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative Rhabdomyosarcoma 94%
Similar papers in this journal
- Timing anti-PD-L1 checkpoint blockade immunotherapy to enhance tumor irradiation 96%
- GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumors 94%
- Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia 91%
Similar papers in this journal
- FLASH Bragg-peak irradiation with a therapeutic carbon ion beam: first in vivo results 95%
- MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer 95%
- Pharmacologic manipulation of complement receptor 3 prevents dendritic spine loss and cognitive impairment after acute cranial radiation 94%
Similar papers in this journal
- Modulating the unfolded protein response: Impacts of radiation on the response of prostate cancer cells to ONC201 94%
- Feeding Drosophila highly radioresistant fungi improves survival and gut morphology following acute gamma radiation exposure 94%
- Genome-wide transcriptomic response of whole blood to radiation 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.